Bevacizumab appears more effective than laser therapy in patients with center-involving CSME

This prospective, masked, single-center trial randomized 80 patients (80 eyes) with center-involving clinically significant diabetic macular edema and at least one prior macular laser therapy (MLT) to intravitreal bevacizumab (six weekly) or MLT (four monthly). Mean BCVA at 12 months was 61.3 in the bevacizumab group and 50 in the laser group (P = 0.0006). The bevacizumab group gained a median of eight  letters, while the laser group lost 0.5 (P = 0.0002), and the odds of gaining at least 10 letters over 12 months were more than five times greater in the bevacizumab group.